Blockchain Registration Transaction Record

Liquid Biopsy Predicts Immunotherapy Response in Lung Cancer

New liquid biopsy predicts immunotherapy response in advanced lung cancer, offering a simpler way to personalize treatment. Learn how this breakthrough may impact patients and drug developers like Calidi Biotherapeutics.

This news matters because it addresses a critical challenge in cancer treatment: predicting which patients will benefit from immunotherapy. By offering a simple blood test to forecast responses, this liquid biopsy could spare patients from ineffective treatments and their side effects, while also helping drug developers like Calidi Biotherapeutics optimize clinical trials. Ultimately, this could lead to more personalized and effective cancer care, improving survival rates and quality of life for lung cancer patients.